

**11-TTAG-031**

<b>Company Name</b>	Ascendant, LLC
<b>NAICS</b>	541712
<b>Address</b>	535 W. Research Center BLVD Suite 135
<b>City</b>	Fayetteville
<b>State</b>	AR
<b>ZIP</b>	72701
<b>County</b>	Washington
<b>Number of Employees</b>	13
<b>Year Established</b>	2009
<b>Company Web Site</b>	<a href="#">Client Company of Virtual Incubation</a>
<b>Contact Person</b>	Calvin Goforth
<b>Title</b>	President
<b>Phone</b>	479-571-2592
<b>Email Address</b>	<a href="mailto:calvin.goforth@virtual-incubation.com">calvin.goforth@virtual-incubation.com</a>
<b>Fax</b>	479-571-8814
<b>Secondary Contact Name</b>	Mark Kidd
<b>Secondary Contact Title</b>	VP of Finance and Admin
<b>Secondary Contact Phone</b>	479-571-2592
<b>Secondary Contact Email</b>	<a href="mailto:mkidd@virtual-incubation.com">mkidd@virtual-incubation.com</a>
<b>Resource Provider</b>	Ascendant, LLC
<b>RP Address</b>	535 W. Research Center BLVD Suite 135
<b>RP City</b>	Fayetteville
<b>RP State</b>	AR
<b>RP ZIP</b>	72701
<b>RP County</b>	Washington

<b>RP Project Contact</b>	Mark Kidd
<b>RP Title</b>	VP Finance and Admin
<b>RP Phone</b>	479-571-2592
<b>RP Email</b>	<a href="mailto:mkidd@virtual-incubation.com">mkidd@virtual-incubation.com</a>
<b>RP Fax</b>	479-571-8814
<b>Project Area</b>	<a href="#">Biotechnology, Bioengineering, Agriculture and Life Sciences - 17 - Other Medical Biotechnologies (Please provide short description in box provided below)</a>
<b>Project Area Brief Description</b>	This development effort seeks to identify and validate new protein biomarkers capable of detecting the presence of breast cancer as a screening tool for dramatically improving early detection of the disease.
<b>Federal Agency</b>	<a href="#">U.S. Department of Health and Human Services</a>
<b>Project Title</b>	11-TTAG-031 - Novel Proteomic Biomarkers for Early Breast Cancer Detection
<b>Competitive Challenges</b>	Ascendant is developing innovative new approaches to identify and validate new protein biomarkers capable of detecting the presence of breast cancer as a screening tool for dramatically improving early detection of the disease.
<b>Specific Problem</b>	NIH (National Institute of Health) This development effort seeks to identify and validate new protein biomarkers capable of detecting the presence of breast cancer as a screening tool for dramatically improving early detection of the disease. Currently, patient survival is significantly reduced once a tumor has been detected by conventional imaging methods (mammograms, MRI, etc) and patient participation in breast cancer screening is lower due to the discomfort and invasiveness of the various diagnostic tests associated with the disease. With the identification of unique proteomic signatures, early and improved treatments tailored to the specific needs of patients may be developed and greater participation will be seen in early testing from risk groups due to the ease and comfort of the proposed diagnostics in this effort. This potential detection method is enabled through a growing body of research evidence that supports the "peptidome hypothesis" and suggests that biological fluids such as serum, plasma, and tears, contain protein biomarkers that when measured in combination, provide a wealth of information about the biological status of an individual patient.
<b>Solution</b>	This specific research effort is based on a preliminary study by Dr. Larry Suva and Dr. Suzanne Klimberg from the University Of Arkansas School for Medical

	Sciences utilizing human tears, the filtered product of the blood, that have shown to contain discriminatory proteins that, once identified, have utility as biomarkers or diagnostic indicators of breast cancer. Tears offer significant advantages for proteome analyses, as collection is easy and non-invasive to the patient.
<b>Implementation Plan</b>	Ascendant seeks to identify and validate new protein biomarkers capable of detecting the presence of breast cancer as a superior screening tool for improving early breast cancer screening and detection, monitoring response to therapy, and/or detecting early recurrence. Specific Aims: Secondary Tear Sample Acquisition, Analysis, and Interpretation of the Results Independent Verification of the Preliminary Studies Data and Analysis of the Results Develop Principal Laboratory, Equipment, and Sample Procedures and Methodologies
<b>Maintenance Plan</b>	Ascendant, LLC will maintain the solution by obtaining and federal regularity. Also, partnering with services to further the research. We will also seek investment funding
<b>Step 1</b>	Preparatory Work: -Define Research Objectives -Outline Proposal -Discussions with funding agencies -Literature search and review -Identification of potential users and partners
<b>Step 1 Time</b>	20.00
<b>Step 1 Budget</b>	\$1,000
<b>Step 2</b>	Proposal Content Development -Technology Description -Work plan development - Budget Development -Commercialization Plan
<b>Step 2 Time</b>	50.00
<b>Step 2 Budget</b>	\$2,500
<b>Step 3</b>	Final Proposal Preparation - Proposal Review - Formatting and Proofreading - Letters of support, consultant letters - Agency Forms - Cover letters, copies, mailing
<b>Step 3 Time</b>	30.00
<b>Step 3 Budget</b>	\$1,500
<b>Increased Sales</b>	\$0
<b>Retained Sales</b>	\$0
<b>CS Inventory</b>	\$0

<b>CS Labor</b>	\$0
<b>CS Materials</b>	\$0
<b>CS Other</b>	\$0
<b>II Plant</b>	\$0
<b>II IS</b>	\$0
<b>II Workforce</b>	\$0
<b>II Research</b>	\$150,000
<b>II Other</b>	\$0
<b>AUI</b>	\$0
<b>SOI</b>	\$0
<b>Job Retention</b>	0
<b>Job Creation</b>	1
<b>YN 90Days</b>	No
<b>YN Affiliation</b>	Yes
<b>YN Agreement</b>	Yes
<b>YN Total Project Price</b>	Yes
<b>Explain Total Project Price</b>	
<b>YN Cash Match Agreement</b>	Yes
<b>Copied</b>	No
<b>TTAG ID</b>	11-TTAG-031
<b>Signature Panel - RP AR Name</b>	Mark Kidd
<b>Signature Panel - RP AR Email</b>	<a href="mailto:mkidd@virtual-incubation.com">mkidd@virtual-incubation.com</a>
<b>Signature Panel - Enterprise AR Name</b>	Calvin Goforth
<b>Enterprise - Email</b>	.....
<b>Signature Panel - Enterprise AR Email</b>	<a href="mailto:calvin.goforth@virtual-incubation.com">calvin.goforth@virtual-incubation.com</a>
<b>Include in Batch</b>	Yes

<b>Batch Number</b>	NA
<b>Application Status</b>	Pending
<b>Organization</b>	ASTA
<b>BatchTest</b>	Processed
<b>Batch Date</b>	
<b>Set Batch Number</b>	
<b>Lvl4</b>	No
<b>Application Description</b>	8-Biotechnology, Bioengineering & Life Sciences
<b>SBIR-STTR</b>	Yes